Status:

COMPLETED

NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia

Lead Sponsor:

AstraZeneca

Conditions:

Schizophrenia

Eligibility:

All Genders

18-80 years

Brief Summary

The purpose of the study is to monitor the general functional changes among patients with schizophrenia, treated with atypical antipsychotics dosed once daily for a period of 6 months.The primary stud...

Eligibility Criteria

Inclusion

  • patients have a diagnosis of schizophrenia, as defined by DSM-IV-TR
  • patients' symptoms are controlled with Seroquel SR started up to 1 month before the inclusion
  • or patients' symptoms are controlled with other atypical antipsychotic in once daily formulation started up to 1 month before the inclusion

Exclusion

  • patients who are treated with Seroquel SR or other antipsychotic more than 1 month
  • patients with prescribed antipsychotic combinations
  • pregnant women or women who are breast-feeding
  • patients who have been treated with antipsychotics in depot formulations for the last two months

Key Trial Info

Start Date :

February 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 1 2010

Estimated Enrollment :

106 Patients enrolled

Trial Details

Trial ID

NCT00833456

Start Date

February 1 2009

End Date

November 1 2010

Last Update

October 14 2011

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

Research Site

Begunje na Gorenjskem, Slovenia

2

Research Site

Brezovica pri Ljubljani, Slovenia

3

Research Site

Brežice, Slovenia

4

Research Site

Idrija, Slovenia

NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia | DecenTrialz